Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

BAKER CAPITAL STRATEGIES

Get the free weekly BCS email.

Selected company filings and market updates, delivered by email. Your first report will follow soon.

  • Your weekly BCS reportMarket updates and links to filings you can explore.
  • THEMA at launchWe’ll send directions for setting up your filing alerts when THEMA officially opens.

One signup for the weekly email and your free THEMA Basic account at launch.

Already registered or a CSW member?Log in to THEMA →

At least 8 characters. This also creates your free THEMA account for launch.

You’re signing up for the weekly BCS email and THEMA launch/setup updates. Unsubscribe using the link in any email. Privacy policy · Terms

BCS

Current Report · Items 3.02, 7.01, 9.01 · 8-K

Caring Brands, Inc.

CABRNASDAQEQUITYCurrent

Unregistered Sales of Equity Securities · Regulation FD Disclosure

Item 3.02 As previously disclosed in the Current Report on Form 8-K filed by Caring Brands, Inc. (the “Company”) with the Securities and Exchange Commission (the “SEC”) on August 25, 2026 (the “August 25 Report”), on August 21, 2026, the Company entered into a Securities Purchase Agreement (the “Purchase Agreement”) with certain accredited investors (collectively, the “Investors”), pursuant to whi…

Filed Sep 11, 2026Accepted Sep 11, 2026, 2:46 PM EDTCIK 2020737Accession 0001493152-26-042368
Share

Company context

We are a wellness consumer products company. We offer several over-the-counter (OTC) and cosmetic consumer products. Our product pipeline includes a diverse range of products, such as hair loss treatments, eczema and psoriasis treatments, vitiligo solutions, a jellyfish sting protective suncare line, and women’s sexual wellness products, catering to diverse health and wellness needs. Our method of operation ensures that (1) the mechanism of action of all products is established, (2) efficacy is determined through controlled clinical trials, (3) products are protected by issued and filed patents, and (4) products have acceptable commercial stability.

Current securities

Historical securities (2)

Recent company filings

  1. EFFECT filingNov 5, 2026
  2. S-1 filingOct 27, 2026
  3. Material Modification to Rights of Security Holders · Amendments to Articles of Incorporation or Bylaws; Change in Fiscal YearOct 22, 2026
  4. 4 filingOct 16, 2026
  5. 4 filingSep 30, 2026

Registered securities in this filing

Caring Brands, Inc. · 8-K · Filed 2026-09-11

As filed in this accession. Current/historical status below comes from the governed listing record; the cover itself remains exact to this filing.

Common Stock, par value $0.001 per share

Symbol
CABR
Exchange
NASDAQ
Classification
COMMON
Status
Current
Filing context

Context: AsOf2026-09-11

Dimensions: Not supplied

Accession 000149315226042368 · 1 registered-security cover member

Read the exact SEC filing ↗

Disclosure sections

Items 3.02, 7.01, 9.01

Select an item to read the extracted section. The as-filed document remains the primary evidence.

Item 3.02Item 3.02 - Unregistered Sales of Equity
Item 3.02 As previously disclosed in the Current Report on Form 8-K filed by Caring Brands, Inc. (the “Company”) with the Securities and Exchange Commission (the “SEC”) on August 25, 2026 (the “August 25 Report”), on August 21, 2026, the Company entered into a Securities Purchase Agreement (the “Purchase Agreement”) with certain accredited investors (collectively, the “Investors”), pursuant to which the Company agreed to issue and sell to the Investors, in a private placement (the “Offering”), up to 11,000 shares of the Company’s Series B Convertible Preferred Stock, par value $0.001 per share (the “Series B Preferred Stock”), at a purchase price of $1,000 per share, together with Common Stock Purchase Warrants A (the “Series A Warrants”) and Common Stock Purchase Warrants B (the “Series B Warrants” and, together with the Series A Warrants, the “Warrants”) to purchase shares of the Company’s common stock, par value $0.001 per share (the “Common Stock”), at exercise prices of $0.825 and $0.95 per share, respectively. As previously disclosed in the Current Report on Form 8-K filed with the SEC on September 1, 2026 (the “September 1 Report”), on September 1, 2026, the Company completed an initial closing under the Purchase Agreement (the “Initial Closing”), at which it issued 4,600 shares of Series B Preferred Stock, Series A Warrants to purchase up to 4,600,000 shares of Common Stock and Series B Warrants to purchase up to 4,600,000 shares of Common Stock, for aggregate gross proceeds of $4,600,000. On September 11, 2026, the Company completed an additional closing under the Purchase Agreement (the “Subsequent Closing”), at which the Company issued and sold to certain of the Investors (i) 2,549.9 shares of Series B Preferred Stock, (ii) Series A Warrants to purchase up to 2,549,900 shares of Common Stock and (iii) Series B Warrants to purchase up to 2,549,900 shares of Common Stock, for aggregate gross proceeds of $2,549,900. The shares of Series B Preferred Stock issued at the Subsequent Closing are initially convertible into an aggregate of 3,642,714 shares of Common Stock at the initial conversion price of $0.70 per share, subject to adjustment and subject to the 19.99% exchange cap (the “Exchange Cap”) and the beneficial ownership limitations described in the August 25 Report. Following the Subsequent Closing, the Company has issued in the Offering an aggregate of 7,149.9 shares of Series B Preferred Stock, Series A Warrants to purchase up to 7,149,900 shares of Common Stock and Series B Warrants to purchase up to 7,149,900 shares of Common Stock, for aggregate gross proceeds of $7,149,900. The September 1 Report disclosed that, as of its date, subscription documents for an additional $4,400,000 had been executed and that the Company expected the related funds to be released on or before September 4, 2026. The Company may complete one or more additional closings under the Purchase Agreement with respect to the remaining amount of such subscriptions; however, no assurance can be given that any such closing will occur, in whole or in part, or as to its timing. The unaudited pro forma balance sheet included under Item 7.01 below does not give effect to any such additional closing. All shares of Series B Preferred Stock and Warrants issued at the Subsequent Closing were issued solely to Investors that executed the Purchase Agreement on August 21, 2026. The securities described above were offered and sold in reliance upon the exemption from registration afforded by Section 4(a)(2) of the Securities Act of 1933, as amended (the “Securities Act”), and Rule 506(b) of Regulation D promulgated thereunder. Each Investor represented that it is an “accredited investor” as defined in Rule 501(a) of Regulation D. The securities issued in the Offering, and the shares of Common Stock issuable upon conversion or exercise thereof, have not been registered under the Securities Act and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements. The terms of the Purchase Agreement, the Series B Preferred Stock, the Warrants and the Registration Rights Agreement entered into in connection with the Offering (the “Registration Rights Agreement”) are described in the August 25 Report, and such descriptions are incorporated herein by reference. Such descriptions do not purport to be complete and are qualified in their entirety by reference to the full text of the applicable documents, copies of which were filed as exhibits to the August 25 Report and are incorporated herein by reference.
Item 7.01Item 7.01 - Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure. Preliminary Pro Forma Financial Information As previously disclosed, on April 7, 2026, the Company received a notice (the “Notice”) from the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that it was not in compliance with Nasdaq Listing Rule 5550(b)(1) (the “Stockholders’ Equity Requirement”), which requires companies listed on The Nasdaq Capital Market to maintain stockholders’ equity of at least $2,500,000. The Notice was based on the Company’s Annual Report on Form 10-K for the year ended December 31, 2025, which reported stockholders’ equity of $2,091,324. The Company subsequently submitted a plan to regain compliance with the Stockholders’ Equity Requirement. On July 15, 2026, the Company received a Staff Delisting Determination (the “Delisting Determination”) denying the Company’s request for continued listing on The Nasdaq Capital Market. The Company is providing the preliminary, unaudited pro forma condensed consolidated balance sheet as of August 31, 2026 and the accompanying notes furnished as Exhibit 99.1 to this Current Report on Form 8-K (the “Preliminary Pro Forma Information”). The Preliminary Pro Forma Information gives effect to the private placement closings as if they had occurred on August 31, 2026. It reflects preliminary pro forma stockholders’ equity of $8,220,419, exceeding the Stockholders’ Equity Requirement. Nasdaq will continue to monitor the Company’s ongoing compliance with the Stockholders’ Equity Requirement and, if at the time of its next periodic report the Company does not evidence compliance, the Company may be subject to delisting. The Company’s next periodic report will be its Quarterly Report on Form 10-Q for the quarter ending September 30, 2026. The Company intends to submit this Current Report on Form 8-K to the Panel in support of a determination that the Company has regained compliance with the Stockholders’ Equity Requirement. This report and the Preliminary Pro Forma Information are being provided in connection with the Company’s request for a favorable Panel determination. They do not constitute Nasdaq confirmation that the deficiency has been resolved or that the delisting proceedings have been terminated. Based on the completed transactions and management’s assessment of the Company’s financial condition, the Company believes that it has regained compliance with the Equity Requirement. The Company has requested that the Nasdaq Hearings Panel (the “Panel”) resolve the previously disclosed stockholders’ equity deficiency and confirm the Company’s compliance. There can be no assurance that the Panel or Nasdaq will determine that the Company has regained compliance, that any such determination will not be subject to conditions or a monitoring period, or that the Company will be able to maintain compliance with the Stockholders’ Equity Requirement or Nasdaq’s other continued listing requirements. The Preliminary Pro Forma Information was prepared by the Company’s financial personnel and is the responsibility of management. It is preliminary, unaudited and based on information available as of September 11, 2026. The presentation does not include all financial statements and disclosures required by generally accepted accounting principles in the United States (“U.S. GAAP”) and should not be viewed as a substitute for the Company’s financial statements prepared in accordance with U.S. GAAP. It should be read together with the Company’s previously filed financial statements and related notes. The information remains subject to the completion of financial statement preparation, account reconciliations, closing procedures and the finalization of estimates and accounting analyses, as well as adjustments arising from the independent registered public accounting firm’s review of the Company’s quarterly financial statements and audit of its annual financial statements. Potential adjustments include the classification and valuation of preferred stock, warrants and embedded features; the accounting for the Series A amendment; the allocation of financing proceeds and offering costs; preferred dividends; accrued liabilities; compensation expense; and other financial statement items. Final reported amounts may differ materially from the preliminary amounts presented, and any difference could affect the Company’s assessment of compliance with the Equity Requirement. The Preliminary Pro Forma Information reflects only the specified transactions and assumptions described in Exhibit 99.1. It is not a representation of the Company’s actual financial position on September 11, 2026, a projection of results for the quarter ending September 30, 2026 or the year ending December 31, 2026, or an assurance of continued listing. Further operating losses, dividends, expenses or other charges may reduce stockholders’ equity. Investors are cautioned against placing undue reliance on this preliminary information. The information in this Item 7.01, including Exhibit 99.1, is furnished and shall not be deemed “filed” for purposes of Section 18 of the Exchange Act or otherwise subject to the liabilities of that section. It shall not be incorporated by reference into any filing under the Securities Act or the Exchange Act, except to the extent expressly incorporated by specific reference in that filing. This report does not constitute an offer to sell or a solicitation of an offer to buy any securities. The private placement securities have not been registered under the Securities Act and may be offered or sold only pursuant to registration or an applicable exemption. Forward Looking statements This Current Report on Form 8-K contains forward-looking statements. To the extent applicable, the Company intends these statements to be covered by the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). Forward-looking statements include expectations regarding final financial reporting and accounting treatment; the timing and outcome of Nasdaq’s and the Panel’s review; the Company’s ability to regain and maintain compliance with Nasdaq’s continued listing requirements; and future stockholders’ equity, financial condition and capital needs. Words such as “believes,” “expects,” “estimates,” “anticipates,” “intends” and “may” and similar expressions may identify such statements. These statements are based on current expectations and assumptions and involve risks and uncertainties that may cause actual outcomes to differ materially. Those risks include adjustments identified during closing, review and audit procedures; changes to the classification, valuation or accounting treatment of the preferred stock, warrants or related contractual provisions; differences between estimated and actual offering costs; additional operating losses, preferred dividends and other charges; Nasdaq’s exercise of discretion in evaluating both current equity and the ability to sustain compliance; additional conditions or information required by Nasdaq; an adverse Panel determination; the Company’s ability to satisfy other listing standards, obtain required stockholder approvals and comply with its financing and registration rights obligations; and the availability of additional capital if needed. Additional risks are described in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025, and its subsequent reports and other filings with the Securities and Exchange Commission. Forward-looking statements are not guarantees of future performance or of a favorable Nasdaq determination and speak only as of the date made. Except as required by applicable law, the Company undertakes no obligation to publicly update or revise any forward-looking statement as a result of new information, future events or otherwise.
Filed exhibits (1)
EX-99.1 (by filename) ex99-1.htm

EX-99.1 2 ex99-1.htm EX-99.1 Exhibit 99.1 CARING BRANDS, INC. AND SUBSIDIARIES UNAUDITED PRO FORMA CONDENSED CONSOLIDATED BALANCE SHEET As of August 31, 2026 Purpose. This unaudited pro forma condensed consolidated balance sheet is presented to evidence the Company’s stockholders’ equity following significant transactions completed after August 31, 2026. The presentation uses August 31, 2026 as the historical balance-sheet date and separately reflects the post-period transactions that resulted in pro forma compliance with Nasdaq Capital Market Listing Rule 5550(b)(1). Nasdaq standard. Nasdaq Listing Rule 5550(b)(1) requires a Nasdaq Capital Market issuer relying on the Equity Standard to maintain stockholders’ equity of at least $2.5 million. The pro forma stockholders’ equity shown below is approximately $8.2 million. ($) August Post-August Pro 31, 2026 31 Forma Historical Adjustments ────…

Open exhibit ↗

Privacy choices

BCS measures page use with Google Analytics using regional consent settings. You can change your preference here. Charts and market data remain available.

Essential functions — always available. Security, navigation, registration and remembering these choices.

Audience analytics

Analytics cookies are off by default for visitors Google identifies in the EEA, UK or Switzerland until allowed. Limited measurement without analytics cookies may still occur under those regional defaults.

TradingView charts, quotes and the economic calendar load automatically as page content. TradingView receives network and browser information and may collect its own usage analytics. This choice controls BCS’s Google Analytics only.

Google advertising is not enabled. Direct sponsor links do not load advertising trackers on BCS.

Turning analytics off stops future Google Analytics activity here. It does not erase information already received by the provider. Read the privacy policy.